초록

A process for preparing a protein-rich animal feed from waste food is described, wherein the food is cooked with steam, minced, dried, sterilized with radio waves, and put in condition to serve as a feed for protein-producing animals for human consumption.

대표청구항 ▼

A process for preparing a protein-rich animal feed from waste food is described, wherein the food is cooked with steam, minced, dried, sterilized with radio waves, and put in condition to serve as a feed for protein-producing animals for human consumption. hape and comprises a second mixing element

A process for preparing a protein-rich animal feed from waste food is described, wherein the food is cooked with steam, minced, dried, sterilized with radio waves, and put in condition to serve as a feed for protein-producing animals for human consumption. hape and comprises a second mixing element for agitation. 13. The process for producing sustained release microcapsules according to claim 12 wherein the second mixing element is a rotor-grooved stator assembly. 14. The process for producing sustained release microcapsules according to claim 9, wherein the first mixing element is a sonic mixing probe. 15. The process for producing sustained release microcapsules according to claim 12, wherein the first emulsion and the aqueous phase containing a protective hydrophilic colloid are fed into and removed from the second mixer continuously so that the residence time of the solutions in the second mixer is less than 1 seconds and wherein the peripheral rotor speed of the rotor-stator assembly of the second mixer is greater than 9 m/sec. 16. The process for producing sustained release microcapsules according to claim 1, wherein the first mixer comprises an intensive agitator element and an inner tube and wherein the intermixing of the active peptide aqueous solution with the oily polymer phase to form an emulsion comprises injecting both solutions coaxially to the agitator element axis, in the front face of the first intensive agitation equipment, with the aqueous solution entering by the inner tube at a distance from the agitator device not greater than 20 mm. 17. The process for producing sustained release microcapsules according to claim 1, wherein the total feed flow to the first mixer is from about 30 to 500 ml/min. 18. The process for producing sustained release microcapsules according to claim 1, wherein the oily solution of the biodegradable polymer and the aqueous phase containing the active peptide are fed into the first mixer at a mass ratio of about 6:10. 19. The process for producing sustained release microcapsules according to claim 1, wherein the total feed flow to the second mixer is from about 500 to 10,000 ml/min. 20. The process for producing sustained release microcapsules according to claim 1, wherein the intermixing of the first water/oil emulsion into the aqueous phase comprises injecting both flows coaxially to the axis of the agitating element, in the front face of the second intensive agitation equipment, and with the water/oil emulsion entering by the inner tube, at a distance from the agitating device not greater than 20 mm. 21. The process for producing sustained release microcapsules according to claim 1, wherein the aqueous phase and the first emulsion are fed to the second mixer at a mass ratio from about 30:80. 22. The process for producing sustained release microcapsules according to claim 1, wherein the retention substance is a gelatin of bovine origin with a gelation power from about Bloom 75 to Bloom 100, type B, and wherein the gelatin is added to the aqueous solution of the active peptide at a concentration ranging from 0% to 10% in weight. 23. The process for producing sustained release microcapsules according to claim 1, wherein the biodegradable polymer is a copolymer of d,l-lactic acid and glycolic acid, of a molecular weight from about 10,000 to 30,000 Daltons. 24. The process for producing sustained release microcapsules according to claim 19, wherein the molar ratio of the lactic:glycolic acid monomers ranges from 50:50 to 100:0. 25. The process for producing sustained release microcapsules according to claim 1, wherein the organic solvent in the biodegradable polymer organic solution comprises methylene chloride. 26. The process for producing sustained release microcapsules according to claim 1, wherein the protective hydrophilic colloid in the aqueous phase comprises polyvinyl alcohol (PVA) having an apparent viscosity of 25 to 50 centipoise as measured in a 4% by weight aqueous solution at a temperature of 20° C., with an hydrolysis grade from about 85% to 89% and a concentration from about 0.1% to 1% by weight. 27. The process for producing sustained release microcapsules according to claim 1, wherein the lyophilization excipient is mannitol at a concentration from about 0.1 to 5% by weight in the suspension. 28. The process for producing sustained release microcapsules according to claim 1, wherein the microcapsules which have been dispersed into an aqueous phase are dispersed into a vessel suitable for a final dosage, and the aqueous phase in the vessel is frozen in an orbital agitation freezer at temperatures below -20° C., over a period of from 5 to 60 min. 29. The process for producing sustained release microcapsules according to claim 1, wherein the orbital agitation freezer used for freezing is a refrigerated plate with an orbital circular movement where the rotation radius is less than or equal to the radius of the base of the vessel that contains aqueous dispersion of microcapsules. 30. The process for producing sustained release microcapsules according to claim 1, wherein the agitator device makes an orbital circular movement, with a rotation speed from about 20 to 50 r.p.m. 31. The process for producing sustained release microcapsules according to claim 1, wherein the dispersion of microcapsules into an aqueous medium and the subsequent freezing with agitation operations are made in a closed system. 32. The process for producing sustained release microcapsules according to claim 1, wherein the microcapsules, once produced, retain substantially the same size and size distribution and the same active peptide concentration during the entire process. 33. The process for producing sustained release microcapsules according to claim 1, wherein the flow rates of the substances fed to the first and second mixers are independently adjusted. 34. The process for producing sustained release microcapsules according to claim 1, wherein the intensity of the mixing in the first and second mixers are adjusted independently of each other and of the feed flow rates of the substances fed to the mixers. 35. The process for producing sustained release microcapsules according to claim 1, wherein the active peptide is leuprolide acetate. 36. The process for producing sustained release microcapsules according to claim 1, wherein the active peptide is goserelin acetate. 37. The process for producing sustained release microcapsules according to claim 1, wherein the active peptide is nafarelin acetate. 38. The process for producing sustained release microcapsules according to claim 1, wherein the active peptide is triptorelin acetate. 39. The process for producing sustained release microcapsules according to claim 1 wherein the active peptide is buserelin acetate. 40. The process for producing sustained release microcapsules according to claim 1, wherein the active peptide percentage loss in the process is less than 30% of the raw material. 41. The process for producing sustained release microcapsules according to claim 1, wherein the vessel is a dosage vial which after lyophilization is sealed to prepare the final product for consumption. 42. The process for producing sustained release microcapsules according to claim 1, wherein the vessels is a container suitable for bulk sales. 43. The process for producing sustained release microcapsules according to claim 1, wherein the microcapsules resulting from this procedure are not susceptible to agglomeration during a normal period before use, and the suspension reconstitution to be injected is instantaneous. 44. The process for producing sustained release microcapsules according to claim 1, wherein the process can designed so that the microcapsules provide a period of sustained release of the water soluble peptides that is adjustable from about 1 week to about 18 weeks. 45. A microcapsule for the sustained release of water soluble peptides, which microcapsule is produced by the method according to claim 1. 46. A formulation comprising a microcapsule according to claim 41 and other materials 1. 47. A process for producing microcapsules for the sustained release of water soluble peptides, the microcapsules having an adjustable